FDG PET/CT imaging as a biomarker in lymphoma Journal Article


Authors: Meignan, M.; Itti, E.; Gallamini, A.; Younes, A.
Article Title: FDG PET/CT imaging as a biomarker in lymphoma
Abstract: FDG PET/CT has changed the management of FDG-avid lymphoma and is now recommended as the imaging technique of choice for staging and restaging. The need for tailoring therapy to reduce toxicity in patients with a favourable outcome and for improving treatment in those with high-risk factors requires accurate diagnostic methods and a new prognostic algorithm to identify different risk categories. New drugs are used in relapsed/refractory patients. The role of FDG PET/CT as a biomarker in this context is summarized in this review. New trends in FDG metabolic imaging in lymphoma are addressed including metabolic tumour volume measurement at staging and integrative PET which combines PET data with clinical and molecular markers or other imaging techniques. The quantitative approach for response assessment which is under investigation and is used in large ongoing trials is compared with visual criteria. The place of FDG in the era of targeted therapy is discussed. © 2014, Springer-Verlag Berlin Heidelberg.
Keywords: lymphoma; suv; fdg pet; response to treatment; deauville criteria; metabolic tumour volume
Journal Title: European Journal of Nuclear Medicine and Molecular Imaging
Volume: 42
Issue: 4
ISSN: 1619-7070
Publisher: Springer  
Date Published: 2015-04-01
Start Page: 623
End Page: 633
Language: English
DOI: 10.1007/s00259-014-2973-6
PROVIDER: scopus
PUBMED: 25573631
DOI/URL:
Notes: Export Date: 4 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anas Younes
    319 Younes